Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
-
Narrated by:
-
By:
About this listen
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
activate_mytile_page_redirect_t1
What listeners say about Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.